Department of Pediatrics, Harran University School of Medicine, Sanliurfa, Turkey.
J Clin Lab Anal. 2010;24(1):6-11. doi: 10.1002/jcla.20361.
Prolidase is a specific imidodipeptidase involved in collagen degradation. The increase in the enzyme activity is believed to be correlated with the increased intensity of collagen degradation. The study aimed to evaluate the relationship between prolidase activity and oxidative status in patients with thalassemia major.
Comparison was made between 87 patients diagnosed with thalassemia major and 33 healthy children of similar age and gender. Mean age of the subjects was 7.5+/-4.3 years in the group of patients with thalassemia major and 8.9+/-3.1 years in the control group. Serum prolidase activity was measured spectrophotometrically. Oxidative status was determined using total oxidant status (TOS), total antioxidant capacity (TAC), and oxidative stress index (OSI) measurement.
Prolidase activity was significantly increased in patients with thalassemia major (53.7+/-8.7 U/l) compared to the control group (49.2+/-7.2 U/l, P<0.001). TOS was significantly increased in the patient group (5.31+/-3.14 mmol H2O2 equiv./l) compared to the control group (3.49+/-2.98 mumol H2O2 equiv./l) and the OSI was also significantly increased in the patient group (3.86+/-3.28 arbitrary unit) compared to the control group (2.53+/-2.70 arbitrary unit) (P<0.0001 and P<0.001, respectively), while there were no significant differences between the patient (1.61+/-0.30 mumol Trolox equiv./l) and control (1.64+/-0.33 mumol Trolox equiv./l) groups with respect to TAC.
Significant increases in prolidase activity in patients with thalassemia major may constitute a key parameter in demonstrating a disorder of the collagen metabolism.
脯肽酶是一种参与胶原降解的特异性二肽酶。该酶活性的增加被认为与胶原降解强度的增加有关。本研究旨在评估地中海贫血患者中脯肽酶活性与氧化状态之间的关系。
比较了 87 例确诊的地中海贫血患者和 33 名年龄和性别相匹配的健康儿童。地中海贫血组患者的平均年龄为 7.5+/-4.3 岁,对照组为 8.9+/-3.1 岁。采用分光光度法测定血清脯肽酶活性。通过总氧化剂状态(TOS)、总抗氧化能力(TAC)和氧化应激指数(OSI)测定来确定氧化状态。
与对照组(49.2+/-7.2 U/l,P<0.001)相比,地中海贫血患者的脯肽酶活性明显升高(53.7+/-8.7 U/l)。与对照组(3.49+/-2.98 mumol H2O2 equiv./l)相比,患者组的 TOS 明显升高(5.31+/-3.14 mmol H2O2 equiv./l),OSI 也明显升高(3.86+/-3.28 任意单位)与对照组(2.53+/-2.70 任意单位)相比(P<0.0001 和 P<0.001),而患者组(1.61+/-0.30 mumol Trolox equiv./l)与对照组(1.64+/-0.33 mumol Trolox equiv./l)之间的 TAC 无显著差异。
地中海贫血患者脯肽酶活性的显著增加可能构成胶原代谢紊乱的一个关键参数。